Related Experiment Video
Updated: Mar 15, 2026
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
High-content molecular profiling of T-cell therapy in oncology
Ruslan Novosiadly1, Michael Kalos1
1Department of Cancer Immunobiology, Eli Lilly and Company , New York, New York, USA.
Abstract:
Recent clinical data have revealed the remarkable potential for T-cell-modulating agents to induce potent and durable responses in a subset of cancer patients. In this review, we discuss molecular approaches, platforms, and strategies that enable a broader interrogation of the activity of agents that modulate the activity of tumor-specific T cells, to more comprehensively understand how and why the agents succeed and fail, as well as examples of data sets generated in clinical trials that have provided important insights into the biological activity of T-cell therapies and that support further rational development of this exciting treatment modality.
Insights
T-cell-modulating agents show promise in cancer treatment. This review explores strategies to understand how these therapies work and improve their development for better patient outcomes.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Recent clinical data highlight the potential of T-cell-modulating agents in cancer therapy.
- These agents can induce potent and durable responses in a subset of cancer patients.
Purpose of the Study:
- To discuss molecular approaches, platforms, and strategies for interrogating T-cell-modulating agents.
- To comprehensively understand the mechanisms of success and failure of these therapies.
- To support the rational development of T-cell therapies.
Main Methods:
- Review of molecular interrogation strategies.
- Analysis of clinical trial data sets.
- Discussion of biological activity insights.
Main Results:
- Clinical data reveal significant potential for T-cell-modulating agents.
- Interrogation strategies provide deeper understanding of therapy efficacy.
- Clinical trial data offer insights into biological activity.
Conclusions:
- T-cell-modulating agents represent a promising cancer treatment modality.
- Further rational development is supported by comprehensive understanding of their activity.
- Advanced strategies are crucial for optimizing T-cell therapies.
